A share price of MoonLake Immunotherapeutics [MLTX] is currently trading at $46.88, down -3.99%. An important factor to consider is whether the stock is rising or falling in short-term value. The MLTX shares have gain 20.17% over the last week, with a monthly amount glided 24.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MoonLake Immunotherapeutics [NASDAQ: MLTX] stock has seen the most recent analyst activity on May 19, 2025, when Wolfe Research upgraded its rating to a Outperform but kept the price target unchanged to $61 for it. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on March 18, 2025, and set its price target to $67. On January 17, 2025, upgrade upgraded it’s rating to Buy and revised its price target to $82 on the stock. Wolfe Research downgraded its rating to a Peer Perform. Oppenheimer started tracking with a Outperform rating for this stock on June 25, 2024, and assigned it a price target of $104. In a note dated April 02, 2024, Goldman initiated an Neutral rating and provided a target price of $62 on this stock.
MoonLake Immunotherapeutics experienced fluctuations in its stock price throughout the past year between $31.42 and $58.26. Currently, Wall Street analysts expect the stock to reach $67 within the next 12 months. MoonLake Immunotherapeutics [NASDAQ: MLTX] shares were valued at $46.88 at the most recent close of the market. An investor can expect a potential return of 42.92% based on the average MLTX price forecast.
Analyzing the MLTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.22% with Operating Profit Margin at -1210.31%, Pretax Profit Margin comes in at -1447.84%, and Net Profit Margin reading is -1428.72%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.0 and Total Capital is -0.25. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 45.81 points at the first support level, and at 44.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.88, and for the 2nd resistance point, it is at 50.88.
Ratios To Look Out For
To put it in perspective, the Current Ratio for MoonLake Immunotherapeutics [NASDAQ:MLTX] is 21.11. On the other hand, the Quick Ratio is 21.11, and the Cash Ratio is 11.32.
Transactions by insiders
Recent insider trading involved BVF PARTNERS L P/IL, Director, that happened on Oct 04 ’24 when 2.0 million shares were sold. Director, Sturge Simon completed a deal on Oct 04 ’24 to sell 0.17 million shares.
